Caris Life Sciences authorized a share repurchase program of up to $100 million as it continues to scale revenue from molecular profiling services. The program allows open-market and privately negotiated repurchases, with Caris indicating it expects to fund purchases from available cash and cash equivalents. Caris also said it recently submitted an application to New York State’s Clinical Laboratory Evaluation Program to seek authorization for Caris Assure, its blood-based genomic profiling assay, on specimens originating from the state. The company reported Q1 revenue climbing 79% last month. The buyback authorization arrives as Caris seeks additional clinical lab footprint for its liquid biopsy offering, potentially supporting further demand for its platform across oncology treatment decision workflows.